Brain Tumor Research Laboratory, Department of Neurological Surgery, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.
World Neurosurg. 2011 Sep-Oct;76(3-4):270-5. doi: 10.1016/j.wneu.2010.12.055.
Induced pluripotent stem (iPS) cell technology has enormous potential to advance medical therapy by personalizing regenerative medicine and creating novel human disease models for research and therapeutic testing. Before this technology is broadly used in the clinic, we must realistically evaluate its disease modeling and therapeutic potential. Recent advances including the use of iPS cells to successfully model spinal muscular atrophy in vitro, as well as new techniques in generating iPS cells with recombinant proteins have accelerated the prospects of iPS cells for clinical use in regenerative therapy. This review explores the development and limitations of iPS cell technology, presents a critical comparison of iPS cells and embryonic stem cells, and discusses potential clinical applications and future research directions.
诱导多能干细胞（iPS）技术通过个性化再生医学和为研究和治疗测试创建新型人类疾病模型，具有极大的推进医学治疗的潜力。在这项技术广泛应用于临床之前，我们必须现实地评估其疾病建模和治疗潜力。最近的进展包括使用 iPS 细胞在体外成功模拟脊髓性肌萎缩症，以及使用重组蛋白生成 iPS 细胞的新技术，这些都加速了 iPS 细胞在再生治疗中的临床应用前景。本综述探讨了 iPS 细胞技术的发展和局限性，对 iPS 细胞和胚胎干细胞进行了批判性比较，并讨论了潜在的临床应用和未来的研究方向。
